![]() ![]() There’s also an option for researchers to engage Twist in their discovery and optimization work. In exchange for a technology access fee, Stanford researchers can access these libraries through IMA to accelerate antibody discovery against a wide range of therapeutic targets. Stanford and Twist Bioscience have signed a broad agreement enabling Stanford researchers to access Twist’s innovative antibody discovery services as well as its unique “Library of Libraries” for biologics discovery. READ THE TWIST BIOSCIENCE PRESS RELEASE License Agreement IMA seeks to support translational research projects that will develop antibody prototypes by providing access to proprietary technologies from Twist Bioscience. Twist Bioscience Alliance: Antibody Prototyping Porter Alliance for Innovative Medicines (Deerfield). ![]() COVID-19 Response: Outpatient Studies in Human Subjects, Spring 2020.COVID-19 Response: Drug and Vaccine Prototyping, Spring 2020.Small Molecule Drug Prototyping, Fall 2020.High-Throughput Small Molecule Screening, Fall 2020.COVID-19 Response: Drug and Vaccine Prototyping, Fall 2020.Regenerative Therapies for Spinal Muscular Atrophy (SMA), Fall 2020.Regenerative Therapies for Neuromuscular Targets, Spring 2021.High-Throughput Small Molecule Screening, Spring 2021.COVID-19 Response: Outpatient Studies in Human Subjects, Fall 2020.Protein Therapeutics Discovery, Winter 2020.Experimental Human Biology, Winter 2022.Cell, Gene, and Microbiome Therapies, Fall 2022.Small Molecule Drug Prototyping, Fall 2023.Twist Bioscience Corporation (TWST) : Free Stock Analysis Reportįortress Biotech, Inc. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Fortress Biotech currently boasts a Zacks Rank of #4 (Sell). Compared to the company's year-ago EPS, this represents a change of -3.9%. FBIO has returned -4.5% over the past month.įortress Biotech's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.27. One other stock in the same industry, Fortress Biotech (FBIO), finished the last trading session 6.5% higher at $0.81. Twist Bioscience is a member of the Zacks Medical - Biomedical and Genetics industry. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here > The stock currently carries a Zacks Rank #3 (Hold). So, make sure to keep an eye on TWST going forward to see if this recent jump can turn into more strength down the road. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.įor Twist Bioscience, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Revenues are expected to be $56.99 million, up 50.2% from the year-ago quarter. This maker of synthetic DNA for the biotechnology industry is expected to post quarterly loss of $1.28 per share in its upcoming report, which represents a year-over-year change of -52.4%. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |